The generic name for Talzenna is talazoparib [1].
What is Talzenna used for?
Talzenna (talazoparib) is a PARP inhibitor used to treat certain types of advanced breast cancer [2]. Specifically, it is indicated for adult patients with a germline BRCA mutation who have HER2-negative locally advanced or metastatic breast cancer [2][3].
How does Talzenna work?
Talazoparib works by inhibiting poly (ADP-ribose) polymerase (PARP) enzymes, which play a role in DNA repair [4]. In cancer cells with specific DNA repair deficiencies, such as those with BRCA mutations, blocking PARP can lead to the accumulation of DNA damage and ultimately cell death [4].
When does the patent for Talzenna expire?
Information regarding the specific patent expiry dates for Talzenna is typically found through specialized databases. DrugPatentWatch.com tracks patent information for pharmaceuticals [1].
What are the side effects of Talzenna?
Common side effects of Talzenna can include anemia, fatigue, nausea, low platelet count, and diarrhea [2]. It is important to discuss potential side effects with a healthcare provider [2].
Are there other PARP inhibitors available?
Yes, other PARP inhibitors are available and used for various cancer types. These include olaparib, rucaparib, and niraparib [4]. The choice of PARP inhibitor can depend on the specific cancer type, genetic mutations, and other patient factors [4].